1. Home
  2. GIFT vs CALC Comparison

GIFT vs CALC Comparison

Compare GIFT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RDE Inc.

GIFT

RDE Inc.

HOLD

Current Price

$1.11

Market Cap

31.0M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$6.80

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIFT
CALC
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0M
88.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GIFT
CALC
Price
$1.11
$6.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$16.00
AVG Volume (30 Days)
30.6K
103.2K
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$86,142,442.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.42
52 Week High
$2.38
$7.20

Technical Indicators

Market Signals
Indicator
GIFT
CALC
Relative Strength Index (RSI) 54.16 71.29
Support Level $1.02 $5.55
Resistance Level $1.18 $7.20
Average True Range (ATR) 0.07 0.69
MACD 0.01 0.07
Stochastic Oscillator 61.74 86.15

Price Performance

Historical Comparison
GIFT
CALC

About GIFT RDE Inc.

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: